Champions Oncology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Champions Oncology Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CSBR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000771856
Board of directors
-
Daniel Newman Mendelson · DirectorSince 2023
-
David Sidransky · DirectorSince 2023
-
Joel Ackerman · DirectorSince 2023
-
Philip P. Breitfeld · DirectorSince 2023
-
Robert Lawrence Brainin · Director · CEOSince 2021
-
Ronnie Morris · Director · CEOSince 2023
-
Scott R. Tobin · DirectorSince 2023
Chief executives
Robert Lawrence Brainin
· CEO
Since June 2021
Ronnie Morris
· CEO
Until June 2021
· Former
Board connections
2 of this board's directors also sit on 3 other boards.
- via David Sidransky
- via David Sidransky
- via Scott R. Tobin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2025 | Joel Ackerman Director | Option exercise | +94,405 | $2.10 | $198,251 |
| Mar 25, 2025 | Philip P. Breitfeld Director | Other | −4,150 | — | — |
| Oct 31, 2024 | Joel Ackerman Director | Option exercise | +88,470 | $2.10 | $185,787 |
| Oct 31, 2024 | Joel Ackerman Director | Option exercise | +16,667 | $5.43 | $90,502 |
| Jan 12, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +1,000 | $6.50 | $6,500 |
| Jan 11, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +2,000 | $6.27 | $12,540 |
| Jan 10, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +2,944 | $6.31 | $18,577 |
| Jan 9, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +3,000 | $6.25 | $18,750 |
| Jan 8, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +1,000 | $6.15 | $6,150 |
| Jan 5, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +2,000 | $6.09 | $12,180 |
| Jan 4, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +3,000 | $6.12 | $18,360 |
| Jan 3, 2024 | Daniel Newman Mendelson Director | Open-market purchase | +500 | $5.83 | $2,915 |
| Dec 21, 2023 | Daniel Newman Mendelson Director | Open-market purchase | +2,500 | $4.92 | $12,300 |
| Dec 20, 2023 | Daniel Newman Mendelson Director | Open-market purchase | +2,100 | $4.82 | $10,122 |
| Dec 19, 2023 | Daniel Newman Mendelson Director | Open-market purchase | +5,000 | $4.75 | $23,750 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.